

## NEWS RELEASE

# Ligand to Ring the Nasdaq Opening Bell on May 19, 2025

2025-05-14

JUPITER, Fla., May 14, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that the company will ring The Nasdaq Stock Market Opening Bell on Monday, May 19, 2025. CEO Todd Davis will be joined by members of Ligand's senior management team and board of directors to commemorate several recent company milestones, including two value-creating transactions.

"Ringing the Nasdaq Opening Bell marks an exciting milestone in our company's history. Over the past few years, we have made significant progress in transforming Ligand into a profitable and infrastructure-light organization focused on acquiring and generating royalties from a diverse portfolio of biopharmaceutical products," said Todd Davis, CEO of Ligand. "Looking ahead, we remain committed to building on the momentum we've achieved over the past two years, supporting our partners in developing breakthrough medicines for patients, and creating long-term value for our shareholders."

The live broadcast of the Nasdaq Opening Bell ceremony will begin at 9:15 a.m. Eastern Time and will be available at <https://www.nasdaq.com/marketsite/bell-ringing-ceremony>.

### About Ligand Pharmaceuticals

Ligand is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of high-value medicines. Ligand does this by providing financing, licensing our technologies or both. Our business model seeks to generate value for stockholders by creating a diversified portfolio of biotech and pharmaceutical product revenue streams that are supported by an efficient and low corporate

cost structure. Our goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable and diversified manner. Our business model is based on funding programs in mid-to late-stage drug development in return for economic rights, purchasing royalty rights in development stage or commercial biopharmaceutical products and licensing our technology to help partners discover and develop medicines. We partner with other pharmaceutical companies to attempt to leverage what they do best (late-stage development, regulatory management and commercialization) in order to generate our revenue. We operate two infrastructure-light royalty generating technology IP platform technologies. Our Captisol® platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. Our NITRICIL™ platform technology facilitates tunable dosing, permitting an adjustable drug release profile to allow proprietary formulations that target a broad range of indications. We have established multiple alliances, licenses and other business relationships with the world's leading pharmaceutical companies including Amgen, Merck, Pfizer, Jazz, Gilead Sciences and Baxter International. For more information, please visit [www.ligand.com](http://www.ligand.com). Follow Ligand on X and [LinkedIn](#).

We use our investor relations website and X as a means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD. Investors should monitor our website and our X account, in addition to following our press releases, SEC filings, public conference calls and webcasts.

#### Contacts

##### Investors:

Melanie Herman

[investors@ligand.com](mailto:investors@ligand.com)

(858) 550-7761

##### Media:

Kellie Walsh

[media@ligand.com](mailto:media@ligand.com)

(914) 315-6072

Source: Ligand Pharmaceuticals